{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T09:21:52Z","timestamp":1791364912866,"version":"4.3.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T00:00:00Z","timestamp":1738886400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T00:00:00Z","timestamp":1738886400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"National High Level Hospital Clinical Research Funding and National Key Clinical Specialty Project of China","award":["2022-PUMCH-B-092"],"award-info":[{"award-number":["2022-PUMCH-B-092"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Dermatol Res"],"DOI":"10.1007\/s00403-025-03890-z","type":"journal-article","created":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T11:17:55Z","timestamp":1738927075000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Off-label use of JAK1 inhibitor upadacitinib in dermatology"],"prefix":"10.1007","volume":"317","author":[{"given":"Tian-Yi","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue-Ping","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,7]]},"reference":[{"key":"3890_CR1","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.jaci.2022.09.023","volume":"151","author":"E Guttman-Yassky","year":"2023","unstructured":"Guttman-Yassky E, Thyssen JP, Silverberg JI et al (2023) Safety of upadacitinib in moderate-to-severe atopic dermatitis: an integrated analysis of phase 3 studies. J Allergy Clin Immunol 151:172\u2013181. https:\/\/doi.org\/10.1016\/j.jaci.2022.09.023","journal-title":"J Allergy Clin Immunol"},{"key":"3890_CR2","doi-asserted-by":"publisher","first-page":"2513","DOI":"10.1016\/S0140-6736(18)31116-4","volume":"391","author":"MC Genovese","year":"2018","unstructured":"Genovese MC, Fleischmann R, Combe B et al (2018) Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial. Lancet 391:2513\u20132524. https:\/\/pubmed.ncbi.nlm.nih.gov\/29908670","journal-title":"Lancet"},{"key":"3890_CR3","doi-asserted-by":"publisher","first-page":"2303","DOI":"10.1016\/S0140-6736(19)30419-2","volume":"393","author":"JS Smolen","year":"2019","unstructured":"Smolen JS, Pangan AL, Emery P et al (2019) Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study. Lancet 393:2303\u20132311. https:\/\/doi.org\/10.1016\/S0140-6736(19)30419-2","journal-title":"Lancet"},{"key":"3890_CR4","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1136\/annrheumdis-2020-218870","volume":"80","author":"PJ Mease","year":"2021","unstructured":"Mease PJ, Lertratanakul A, Anderson JK et al (2021) Upadacitinib for psoriatic arthritis refractory to biologics: SELECT-PsA 2. Ann Rheum Dis 80:312\u2013320. https:\/\/doi.org\/10.1136\/annrheumdis-2020-218870","journal-title":"Ann Rheum Dis"},{"key":"3890_CR5","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1016\/S0140-6736(19)32534-6","volume":"394","author":"D Van Der Heijde","year":"2019","unstructured":"Van Der Heijde D, Song I-H, Pangan AL et al (2019) Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): a multicentre, randomised, double-blind, placebo-controlled, phase 2\/3 trial. Lancet 394:2108\u20132117. https:\/\/doi.org\/10.1016\/S0140-6736(19)32534-6","journal-title":"Lancet"},{"key":"3890_CR6","doi-asserted-by":"publisher","first-page":"S022","DOI":"10.1093\/ecco-jcc\/jjab075.023","volume":"15","author":"S Danese","year":"2021","unstructured":"Danese S, Vermeire S, Zhou W et al (2021) OP24 efficacy and safety of upadacitinib induction therapy in patients with moderately to severely active Ulcerative Colitis: results from the phase 3 U-ACHIEVE study. J Crohn\u2019s Colitis 15:S022\u2013S024. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjab075.023","journal-title":"J Crohn\u2019s Colitis"},{"key":"3890_CR7","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1016\/S0140-6736(21)00589-4","volume":"397","author":"K Reich","year":"2021","unstructured":"Reich K, Teixeira HD, De Bruin-Weller M et al (2021) Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD up): results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 397:2169\u20132181. https:\/\/doi.org\/10.1016\/S0140-6736(21)00589-4","journal-title":"Lancet"},{"key":"3890_CR8","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1146\/annurev-med-051113-024537","volume":"66","author":"JJ O\u2019Shea","year":"2015","unstructured":"O\u2019Shea JJ, Schwartz DM, Villarino AV et al (2015) The JAK-STAT pathway: impact on Human Disease and therapeutic intervention. Annu Rev Med 66:311\u2013328. https:\/\/doi.org\/10.1146\/annurev-med-051113-024537","journal-title":"Annu Rev Med"},{"key":"3890_CR9","doi-asserted-by":"publisher","first-page":"e0203672","DOI":"10.1371\/journal.pone.0203672","volume":"13","author":"LK Hoffman","year":"2018","unstructured":"Hoffman LK, Tomalin LE, Schultz G et al (2018) Integrating the skin and blood transcriptomes and serum proteome in hidradenitis suppurativa reveals complement dysregulation and a plasma cell signature. PLoS ONE 13:e0203672. https:\/\/doi.org\/10.1371\/journal.pone.0203672","journal-title":"PLoS ONE"},{"key":"3890_CR10","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1002\/eji.201646680","volume":"47","author":"K Welsch","year":"2017","unstructured":"Welsch K, Holstein J, Laurence A, Ghoreschi K (2017) Targeting JAK\/STAT signalling in inflammatory skin diseases with small molecule inhibitors. Eur J Immunol 47:1096\u20131107. https:\/\/doi.org\/10.1002\/eji.201646680","journal-title":"Eur J Immunol"},{"key":"3890_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jaad.2017.04.1141","volume":"78","author":"LC Strazzulla","year":"2018","unstructured":"Strazzulla LC, Wang EHC, Avila L et al (2018) Alopecia Areata. J Am Acad Dermatol 78:1\u201312. https:\/\/doi.org\/10.1016\/j.jaad.2017.04.1141","journal-title":"J Am Acad Dermatol"},{"key":"3890_CR12","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1111\/j.1529-8019.2011.01413.x","volume":"24","author":"AM Finner","year":"2011","unstructured":"Finner AM (2011) Alopecia Areata: clinical presentation, diagnosis, and unusual cases: Finner AM: Alopecia Areata-clinical presentation. Dermatol Ther 24:348\u2013354. https:\/\/doi.org\/10.1111\/j.1529-8019.2011.01413.x","journal-title":"Dermatol Ther"},{"key":"3890_CR13","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1016\/j.jaad.2019.08.032","volume":"82","author":"HH Lee","year":"2020","unstructured":"Lee HH, Gwillim E, Patel KR et al (2020) Epidemiology of Alopecia Areata, ophiasis, totalis, and universalis: a systematic review and meta-analysis. J Am Acad Dermatol 82:675\u2013682. https:\/\/doi.org\/10.1016\/j.jaad.2019.08.032","journal-title":"J Am Acad Dermatol"},{"key":"3890_CR14","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1007\/s12016-021-08883-0","volume":"61","author":"C Zhou","year":"2021","unstructured":"Zhou C, Li X, Wang C, Zhang J (2021) Alopecia Areata: an update on etiopathogenesis, diagnosis, and management. Clin Rev Allerg Immunol 61:403\u2013423. https:\/\/doi.org\/10.1007\/s12016-021-08883-0","journal-title":"Clin Rev Allerg Immunol"},{"key":"3890_CR15","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1111\/jdv.15489","volume":"33","author":"K Phan","year":"2019","unstructured":"Phan K, Sebaratnam DF (2019) JAK inhibitors for Alopecia Areata: a systematic review and meta-analysis. Acad Dermatol Venereol 33:850\u2013856. https:\/\/doi.org\/10.1111\/jdv.15489","journal-title":"Acad Dermatol Venereol"},{"key":"3890_CR16","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1111\/j.1365-4632.2011.05377.x","volume":"51","author":"C Kr\u00fcger","year":"2012","unstructured":"Kr\u00fcger C, Schallreuter KU (2012) A review of the worldwide prevalence of vitiligo in children\/adolescents and adults. Int J Dermatology 51:1206\u20131212. https:\/\/doi.org\/10.1111\/j.1365-4632.2011.05377.x","journal-title":"Int J Dermatology"},{"key":"3890_CR17","doi-asserted-by":"publisher","first-page":"664","DOI":"10.2340\/00015555-2080","volume":"95","author":"L Yang","year":"2015","unstructured":"Yang L, Wei Y, Sun Y et al (2015) Interferon-gamma inhibits melanogenesis and induces apoptosis in melanocytes: a pivotal role of CD8\u2009+\u2009cytotoxic T lymphocytes in Vitiligo. Acta Derm Venerol 95:664\u2013670. https:\/\/doi.org\/10.2340\/00015555-2080","journal-title":"Acta Derm Venerol"},{"key":"3890_CR18","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.1038\/jid.2011.463","volume":"132","author":"JE Harris","year":"2012","unstructured":"Harris JE, Harris TH, Weninger W et al (2012) A mouse model of Vitiligo with focused epidermal Depigmentation requires IFN-\u03b3 for Autoreactive CD8\u2009+\u2009T-Cell Accumulation in the skin. J Invest Dermatology 132:1869\u20131876. https:\/\/doi.org\/10.1038\/jid.2011.463","journal-title":"J Invest Dermatology"},{"key":"3890_CR19","doi-asserted-by":"crossref","unstructured":"Boyd AS, Neldner KH (1991) Lichen planus. J Am Acad Dermatol. 25:593\u2013619. https:\/\/pubmed.ncbi.nlm.nih.gov\/1791218","DOI":"10.1016\/0190-9622(91)70241-S"},{"key":"3890_CR20","doi-asserted-by":"publisher","first-page":"3098","DOI":"10.1080\/09546634.2022.2116926","volume":"33","author":"A Motamed-Sanaye","year":"2022","unstructured":"Motamed-Sanaye A, Khazaee YF, Shokrgozar M et al (2022) JAK inhibitors in lichen planus: a review of pathogenesis and treatments. J Dermatological Treat 33:3098\u20133103. https:\/\/doi.org\/10.1080\/09546634.2022.2116926","journal-title":"J Dermatological Treat"},{"key":"3890_CR21","doi-asserted-by":"publisher","first-page":"eaav7561","DOI":"10.1126\/scitranslmed.aav7561","volume":"11","author":"S Shao","year":"2019","unstructured":"Shao S, Tsoi LC, Sarkar MK et al (2019) IFN-\u03b3 enhances cell-mediated cytotoxicity against keratinocytes via JAK2\/STAT1 in lichen planus. Sci Transl Med 11:eaav7561. https:\/\/doi.org\/10.1126\/scitranslmed.aav7561","journal-title":"Sci Transl Med"},{"key":"3890_CR22","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1111\/exd.14226","volume":"30","author":"K Pietschke","year":"2021","unstructured":"Pietschke K, Holstein J, Meier K et al (2021) The inflammation in cutaneous lichen planus is dominated by IFN-\u03d2 and IL\u201021\u2014A basis for therapeutic JAK1 inhibition. Exp Dermatol 30:262\u2013270. https:\/\/doi.org\/10.1111\/exd.14226","journal-title":"Exp Dermatol"},{"key":"3890_CR23","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1111\/bjd.20653","volume":"186","author":"S Cro","year":"2022","unstructured":"Cro S, Cornelius VR, Pink AE et al (2022) Anakinra for palmoplantar pustulosis: results from a randomized, double-blind, multicentre, two\u2010staged, adaptive placebo\u2010controlled trial (APRICOT)*. Br J Dermatol 186:245\u2013256. https:\/\/doi.org\/10.1111\/bjd.20653","journal-title":"Br J Dermatol"},{"key":"3890_CR24","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1007\/s13555-021-00504-0","volume":"11","author":"U Mrowietz","year":"2021","unstructured":"Mrowietz U, Burden AD, Pinter A et al (2021) Spesolimab, an anti-interleukin-36 receptor antibody, in patients with Palmoplantar Pustulosis: results of a phase IIa, Multicenter, Double-Blind, randomized, placebo-controlled pilot study. Dermatol Ther (Heidelb) 11:571\u2013585. https:\/\/doi.org\/10.1007\/s13555-021-00504-0","journal-title":"Dermatol Ther (Heidelb)"},{"key":"3890_CR25","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1016\/j.jaad.2019.01.066","volume":"80","author":"U Mrowietz","year":"2019","unstructured":"Mrowietz U, Bachelez H, Burden AD et al (2019) Secukinumab for moderate-to-severe palmoplantar pustular psoriasis: results of the 2PRECISE study. J Am Acad Dermatol 80:1344\u20131352. https:\/\/doi.org\/10.1016\/j.jaad.2019.01.066","journal-title":"J Am Acad Dermatol"},{"key":"3890_CR26","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1001\/jamadermatol.2019.1394","volume":"155","author":"T Terui","year":"2019","unstructured":"Terui T, Kobayashi S, Okubo Y et al (2019) Efficacy and safety of Guselkumab in Japanese patients with Palmoplantar Pustulosis: a phase 3 Randomized Clinical Trial. JAMA Dermatol 155:1153. https:\/\/doi.org\/10.1001\/jamadermatol.2019.1394","journal-title":"JAMA Dermatol"},{"key":"3890_CR27","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1016\/j.jaci.2022.04.027","volume":"150","author":"D McCluskey","year":"2022","unstructured":"McCluskey D, Benzian-Olsson N, Mahil SK et al (2022) Single-cell analysis implicates TH17-to-TH2 cell plasticity in the pathogenesis of palmoplantar pustulosis. J Allergy Clin Immunol 150:882\u2013893. https:\/\/doi.org\/10.1016\/j.jaci.2022.04.027","journal-title":"J Allergy Clin Immunol"},{"key":"3890_CR28","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.jaut.2010.06.012","volume":"35","author":"CP Mavragani","year":"2010","unstructured":"Mavragani CP, Crow MK (2010) Activation of the type I interferon pathway in primary Sjogren\u2019s syndrome. J Autoimmun 35:225\u2013231. https:\/\/doi.org\/10.1016\/j.jaut.2010.06.012","journal-title":"J Autoimmun"},{"key":"3890_CR29","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1111\/ijd.14064","volume":"57","author":"JS Kahn","year":"2018","unstructured":"Kahn JS, Deverapalli SC, Rosmarin DM (2018) JAK - STAT signaling pathway inhibition: a role for treatment of discoid lupus erythematosus and dermatomyositis. Int J Dermatol 57:1007\u20131014. https:\/\/doi.org\/10.1111\/ijd.14064","journal-title":"Int J Dermatol"},{"key":"3890_CR30","unstructured":"Muangchan C, Pope JE (2013) The significance of interleukin-6 and C-reactive protein in systemic sclerosis: a systematic literature review. Clin Exp Rheumatol. 31:122\u201334. https:\/\/pubmed.ncbi.nlm.nih.gov\/23910616"}],"container-title":["Archives of Dermatological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-025-03890-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00403-025-03890-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-025-03890-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T11:18:02Z","timestamp":1738927082000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00403-025-03890-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,7]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3890"],"URL":"https:\/\/doi.org\/10.1007\/s00403-025-03890-z","relation":{},"ISSN":["1432-069X"],"issn-type":[{"value":"1432-069X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,7]]},"assertion":[{"value":"15 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 January 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 February 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"363"}}